Pantarhin Pharma Inc. introduces BELACT, a biotechnologically produced, dual action like hyaluronidase. This innovative enzyme combines the activities of PH20 and HYAL4 into a single molecule, making it a unique solution for tackling atherosclerosis. BELACT stands apart by effectively breaking down both hyaluronic acid and sulfated glycosaminoglycans, key components of the extracellular matrix crucial in the development of atherosclerosis.
BELACT’s unique mechanism of action targets and breaks down the building blocks of atherosclerotic plaques, proteoglycans and hyaluronic acid, while preserving the integrity of blood vessels. This allows the vessel wall’s natural repair mechanisms to function without hindrance. Unlike current therapies that often only stabilise or bypass deposits, BELACT actively reduces them, addressing the root cause of the pathophysiology rather than just treating symptoms.
A key differentiating feature is BELACT’s recombinant production, ensuring a completely biotechnological process free from animal components, adhering to GMP guidelines for sustainability. Furthermore, BELACT demonstrates high activity in standardised in vitro tests, showcasing significantly higher specific activity compared to established animal hyaluronidase preparations. Preclinical and clinical studies support its safety profile and dosage.
BELACT offers clinical relevance by ‘cleaning up the vessels from the inside’, breaking down pathological deposits without harming healthy vascular tissue. This targeted approach aims to restore the natural flexibility of blood vessels by eliminating pathological ECM components. The industrially scalable process ensures a reliable supply even for large patient groups, marking a significant step forward in atherosclerosis treatment.